Clincosm LogoSign in Get a demo

Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic

Sponsor
Hacettepe University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04745923
Collaborator
(none)
28
Enrollment
1
Location
2.3
Anticipated Duration (Months)
12.4
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In the literature, there are no studies evaluating fear of COVID-19, anxiety, depression, physical activity, fear of movement and quality of life in patients with chronic kidney disease during COVID-19 pandemic. The investigators will evaluate these parameters in patients with chronic kidney disease and compare the findings of healthy individuals during COVID-19 pandemic

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    28 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Fear of COVID-19 and Physical Activity Level in Patients With Chronic Kidney Disease During COVID-19 Pandemic
    Actual Study Start Date :
    Jan 20, 2021
    Anticipated Primary Completion Date :
    Feb 28, 2021
    Anticipated Study Completion Date :
    Mar 30, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    Patients with chronic kidney disease

    Having been diagnosed with chronic kidney disease
    Healthy individuals

    Healthy individuals without chronic disease

    Outcome Measures

    Primary Outcome Measures

    1. Fear of COVID-19 [5 minutes]

      COVID-19 phobia will be evaluated using Fear of COVID-19 Scale.

    2. Physical activity [5 minutes]

      Physical activity level will be evaluated using International Physical Activity Questionnaire - Short Form (IPAQ-SF).

    Secondary Outcome Measures

    1. Qol [10 minutes]

      Quality of life will be evaluated using SF-36

    2. Anxiety and depression [5 minutes]

      Anxiety and depression will be evaluated using Hospital Anxiety and Depression scale (HADS).

    3. Fear of movement [10 minutes]

      Fear of movement will be evaluated using the Tampa Scale for Kinesiophobia

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Having been diagnosed with chronic kidney disease

    • Being clinically stable

    • Volunteering to participate in the research

    Exclusion Criteria:

    • Having a cognitive problem

    • Not being literate

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hacettepe University, Faculty of Physical Therapy and Rehabilitation Ankara Turkey

    Sponsors and Collaborators

    • Hacettepe University

    Investigators

    • Principal Investigator: Merve Firat, MSc, Hacettepe University
    • Study Director: Naciye Vardar-Yagli, PhD, Hacettepe University
    • Study Chair: Tolga Yildirim, MD, Hacettepe University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Merve Firat, Research assistant, Hacettepe University
    ClinicalTrials.gov Identifier:
    NCT04745923
    Other Study ID Numbers:
    • GO 21/127
    First Posted:
    Feb 9, 2021
    Last Update Posted:
    Feb 9, 2021
    Last Verified:
    Jan 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Merve Firat, Research assistant, Hacettepe University
    Fear
    Quality of life
    Anxiety
    Depression
    Additional relevant MeSH terms:
    COVID-19
    Kidney Diseases
    Renal Insufficiency, Chronic

    Study Results

    No Results Posted as of Feb 9, 2021